These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 25362113)

  • 21. Pharmacological properties of angiotensin II antagonists: examining all the therapeutic implications.
    Unger T
    J Renin Angiotensin Aldosterone Syst; 2001 Sep; 2 Suppl 2():S4-7. PubMed ID: 11881101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
    Schindler C
    Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A meta-analysis of the effect of angiotensin receptor blockers and calcium channel blockers on blood pressure, glycemia and the HOMA-IR index in non-diabetic patients.
    Yang Y; Wei RB; Xing Y; Tang L; Zheng XY; Wang ZC; Gao YW; Li MX; Chen XM
    Metabolism; 2013 Dec; 62(12):1858-66. PubMed ID: 24050270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecule-specific effects of angiotensin II-receptor blockers independent of the renin-angiotensin system.
    Kurtz TW; Pravenec M
    Am J Hypertens; 2008 Aug; 21(8):852-9. PubMed ID: 18535538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal protection with angiotensin receptor blockers: where do we stand.
    Schmieder RE; Ruilope LM; Barnett AH
    J Nephrol; 2011; 24(5):569-80. PubMed ID: 21404225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AT1 receptor autoantibodies mediate effects of metabolic syndrome on dopaminergic vulnerability.
    Pedrosa MA; Labandeira CM; Valenzuela R; Quijano A; Sanchez-Andrade M; Suarez-Quintanilla JA; Lanciego JL; Labandeira-Garcia JL; Rodriguez-Perez AI
    Brain Behav Immun; 2023 Feb; 108():255-268. PubMed ID: 36535607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of angiotensin II receptor blockers on dementia.
    Mogi M; Horiuchi M
    Hypertens Res; 2009 Sep; 32(9):738-40. PubMed ID: 19727113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
    Horký K
    Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prophylactic angiotensin type 1 receptor antagonism confers neuroprotection in an aged rat model of postoperative cognitive dysfunction.
    Li Z; Cao Y; Li L; Liang Y; Tian X; Mo N; Liu Y; Li M; Chui D; Guo X
    Biochem Biophys Res Commun; 2014 Jun; 449(1):74-80. PubMed ID: 24814703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Telmisartan suppresses cerebral injury in a murine model of transient focal ischemia.
    Kasahara Y; Taguchi A; Uno H; Nakano A; Nakagomi T; Hirose H; Stern DM; Matsuyama T
    Brain Res; 2010 Jun; 1340():70-80. PubMed ID: 20388500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
    St Peter WL; Odum LE; Whaley-Connell AT
    Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The chemical biology of clinically tolerated NMDA receptor antagonists.
    Chen HS; Lipton SA
    J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of kinins in the treatment of cardiovascular diseases.
    Regoli D; Plante GE; Gobeil F
    Pharmacol Ther; 2012 Jul; 135(1):94-111. PubMed ID: 22537664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pleiotropic effects of ARB in metabolic syndrome.
    Yamada S
    Curr Vasc Pharmacol; 2011 Mar; 9(2):158-61. PubMed ID: 21143168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renin-angiotensin-aldosterone blockade for cardiovascular disease prevention.
    Vijayaraghavan K; Deedwania P
    Cardiol Clin; 2011 Feb; 29(1):137-56. PubMed ID: 21257105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
    Ruilope LM
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug repurposing for drug development in stroke.
    Fagan SC
    Pharmacotherapy; 2010 Jul; 30(7 Pt 2):51S-4S. PubMed ID: 20575622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin Mediated Oxidative Stress and Neuroprotective Potential of Antioxidants and AT1 Receptor Blockers.
    Prusty SK; Sahu PK; Subudhi BB
    Mini Rev Med Chem; 2017; 17(6):518-528. PubMed ID: 27781960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuronal injury in chronic CNS inflammation.
    Zindler E; Zipp F
    Best Pract Res Clin Anaesthesiol; 2010 Dec; 24(4):551-62. PubMed ID: 21619866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension.
    Tocci G; Sciarretta S; Facciolo C; Volpe M
    Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):767-76. PubMed ID: 17605654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.